Vermont Department of Health Immunization Program Communication
E-mailed: 09.28.2022
Subject: Pre-Orders of Pfizer 5+ Bivalent Open to Some October 3rd

**You are receiving this message as a COVID-19 enrolled provider contact of the Immunization Program. Please forward within your organization as appropriate**

We anticipate that the Pfizer bivalent booster for those 5-11 will be available in mid-October, and we know many of you are excited to get this vaccine in your offices. Initial Vermont allocation is higher than expected and allows for distribution to pediatric primary care while still leaving equitable access throughout the state at community walk-in clinics.

**Offices that plan to administer an initial 100 doses within two weeks of receipt may place an order for 100 doses of Pfizer pediatric bivalent booster Monday, October 3 through NOON Tuesday, October 4.**

**Pre-Ordering Guidance**
- Pre-ordered pediatric bivalent Pfizer will be delivered through the distributor shortly after vaccine approval, anticipated in the 2nd week of October.
- The new bivalent Pfizer product will be added to VIMS on 10/03 at 8 am and removed on 10/04 at noon. Pre-orders requested after noon on 10/04 are unlikely to be fulfilled.
- Do not pre-order more than 100 doses.
  - If you can use more than 100 doses in two weeks, leave a note in the comments of VIMS with details of your planning.
  - Once all state orders are in on October 4, any remaining allocation may be distributed to offices with higher throughput.

**Routine Ordering Guidance**
- Routine ordering will open up following vaccine approval. Please wait for routine ordering guidance if:
  - You do not see many children 5-11 years. There will be plenty of availability in the community to meet initial demand.

AHS.VDHImmunizationProgram@vermont.gov
You plan to administer boosters only during regular office visits. Only offices that anticipate a high throughput should place a pre-order. You need fewer than 100 doses (transfer through the Vermont Depot)

**Vermont Planning for 5+ Bivalent Boosters**

- If receiving an initial order of pediatric bivalent Pfizer vaccine, [coadministration with flu vaccine](#) and administration to non-patients is strongly encouraged.
- **NEW** grant funding is available through AAPVT and the Immunization Program. See the [AAPVT Amended Grant Application for Flu and COVID-19 Vaccines](#) webpage for more information.
- Pfizer and Moderna bivalent boosters for 5+ will be available along with flu vaccine at [community walk-in clinics](#) and pharmacies throughout the state.
- **Moderna bivalent booster will be available for practices to order in mid-October.** The Immunization program will communicate more on this in the coming weeks.

**Pediatric Pfizer Bivalent Booster Anticipated Details**

- As with the 12+ bivalent booster recommendation, **it is expected that with the approval of bivalent boosters for 5+, monovalent mRNA COVID-19 vaccines will no longer be authorized for booster doses.**
  - Monovalent vaccines are expected to remain appropriate for primary series for this age group.
  - Providers should use clinical judgment in administering monovalent boosters to patients 5-11 leading up to bivalent approval.
- Pfizer bivalent vaccine for 5-11 years is expected to have the following characteristics:
  - 10-dose vials, 100 dose minimum for direct delivery
  - Requires diluent (note: will not be able to opt-out of receiving ancillary kits)
  - Vial with an **orange cap similar to the existing monovalent Pfizer product** for this age group, but with a label that identifies it as a bivalent booster. Monovalent and bivalent products are difficult to distinguish from one another. Please plan vaccine management to avoid administration errors.
Resources:
Resources specific to the new products will not be updated or available until EUA approval. Below you will find recent communications from the Immunization Program and COVID-19 vaccine reference pages to bookmark.

- **Immunization Program COVID-19 Bivalent Booster Update - September 2022**: Recent communication for the 12+ bivalent booster approval contains links to pieces of training, guidance and CDC pages also relevant for 5+ approval.
- **U.S. COVID-19 Vaccine Product Information | CDC**
- **Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC**
- **COVID-19 Vaccine Interim COVID-19 Immunization Schedule for 6 Months of Age and Older | CDC**
- **Pfizer Resources:**
  - **Pfizer-BioNTech COVID-19 Vaccines | FDA**: EUAs for providers and recipients will be available on the FDA site following approval
  - **Pfizer-BioNTech COVID-19 Vaccine Presentations Wall Chart | FDA**
  - **Pfizer-BioNTech COVID-19 Vaccine At A Glance | CDC**
  - **Pfizer Live Trainings | Pfizer Medical Information - US**
- **Moderna Resources**
  - **Moderna COVID-19 Vaccines | FDA**: EUAs for providers and recipients will be available on the FDA site following approval
  - **Moderna COVID-19 Vaccine Presentations Wall Chart | FDA**
  - **Moderna COVID-19 Vaccine At A Glance | CDC**
  - **Moderna Live Trainings | Moderna, Inc.**

Thank you for all you do to serve our communities. If you have any questions on the above, please reach out to AHS.VDHImmunizationProgram@vermont.gov.

The Immunization Program
E-mail: AHS.VDHImmunizationProgram@vermont.gov
Phone: 802-863-7638